Instinct Bio Technical Company Holdings Inc. (NASDAQ:BIOT) shares fell sharply in Tuesday’s after-hours session after the biotechnology company announced a proposed equity purchase facility that could provide up to $150 million in funding over the next three years.

The stock closed Tuesday’s regular session down 51.46% at $1.33 before declining another 20.30% in after-hours trading to $1.06.

The company is a biotechnology firm focused on regenerative medicine, longevity-related technologies and advanced therapeutic platforms.

It recently completed its business combination with Relativity Acquisition Corp. and now trades on the Nasdaq under the ticker BIOT.

Financing Update

The company announced it has entered into an indicative term sheet for a proposed equity purchase facility that would allow it to sell up to $150 million of its common stock over a three-year period.

Under the proposed arrangement, Instinct Bio would have the right, but not the obligation, to direct the sale of shares from time to time, subject to specified conditions and regulatory requirements. Shares issued under the facility would generally be priced based on the volume-weighted average price (VWAP) on the applicable purchase date, less a specified discount.

The company said it intends to use proceeds from the facility to accelerate development of its regenerative medicine platform, fund working capital and pursue strategic acquisitions aimed at expanding its longevity-focused ecosystem.

While the facility provides financing flexibility, investors may view the proposed issuance of additional common stock as a potential source of shareholder dilution.

Read Also: Autonomix Medical (AMIX) Stock Rallies Over 54% After Hours: Here's Why

Trading Metrics

Instinct Bio has a market capitalization of approximately $38.33 million, with a 52-week high of $50.00 and a 52-week low of $1.30.

Over the past 12 months, BIOT shares have declined approximately 86.70%.

Benzinga Edge Stock Rankings show negative price trends across the short-, medium- and long-term time frames.

Disclaimer: This content was produced with the help of AI tools and was reviewed and published by Benzinga editors.

Read Also: Microsoft Earnings ‘Don’t Matter,’ Says Gene Munster Because 'Battle With the Bots' Just Beginning, Analyst Sounds 'Value Trap' Warning

Photo: Who is Danny/Shutterstock